Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Depreciation (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accumulated Depreciation data on record, last reported at $15.2 million in Q1 2026.

  • On a quarterly basis, Accumulated Depreciation rose 4.21% to $15.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.2 million, a 4.21% increase, with the full-year FY2025 number at $15.6 million, up 9.75% from a year prior.
  • Accumulated Depreciation reached $15.2 million in Q1 2026 per FULC's latest filing, down from $15.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for FULC hit a ceiling of $15.6 million in Q4 2025 and a floor of $8.8 million in Q1 2022.
  • A 5-year average of $12.8 million and a median of $13.2 million in 2024 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 31.19% in 2022, then rose 4.21% in 2026.
  • Tracing FULC's Accumulated Depreciation over 5 years: stood at $10.7 million in 2022, then increased by 19.68% to $12.8 million in 2023, then rose by 11.73% to $14.3 million in 2024, then increased by 9.75% to $15.6 million in 2025, then decreased by 2.7% to $15.2 million in 2026.
  • Business Quant data shows Accumulated Depreciation for FULC at $15.2 million in Q1 2026, $15.6 million in Q4 2025, and $15.3 million in Q3 2025.